SCHEMBL5729019

SCHEMBL5729019

O=C(c1ccc(OCCC2CCCCN2)cc1C(F)(F)F)c1c(-c2ccc(O)cc2)noc1-c1ccc(O)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHEK2 O96017 1/20 0.40
SSTR2 P30874 1/20 0.37
CHEK1 O14757 1/20 0.37
CYP1A2 P05177 2/20 0.37
CYP2D6 P10635 2/20 0.37
LMNA P02545 2/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2C9 P11712 1/20 0.37
TSHR P16473 1/20 0.37
CYP2C19 P33261 1/20 0.37
CACNA1F O60840 1/20 0.37
KCNA5 P22460 1/20 0.37
SLC6A2 P23975 1/20 0.37
ADRA1A P35348 1/20 0.37
OPRK1 P41145 1/20 0.37
CACNA1D Q01668 1/20 0.37
KCNH2 Q12809 1/20 0.37
CACNA1S Q13698 1/20 0.37
CACNA1C Q13936 1/20 0.37
SCN5A Q14524 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5729282 0.85 CHEK2 (0.49) CHEK2SSTR2CHEK1CYP2D6LMNA
SCHEMBL5729303 0.84 CHEK2 (0.42) CHEK2SSTR2CHEK1LMNATSHR
SCHEMBL5731064 0.83 CHEK2 (0.45) CHEK2CHEK1CYP2D6LMNACYP3A4
SCHEMBL5729015 0.82 ADORA2A (0.33) CYP1A2CYP2D6LMNACYP3A4TSHR
SCHEMBL7662650 0.82 CHEK2 (0.42) CHEK2SSTR2CHEK1AURKBGNRHR
SCHEMBL5729025 0.82 ESR1 (0.52) CYP2D6LMNACYP3A4CYP2C9TSHR
SCHEMBL5729507 0.82 CHEK2 (0.46) CHEK2SSTR2CHEK1ESR1ESR2
SCHEMBL5729625 0.82 CHEK2 (0.46) CHEK2SSTR2CHEK1ESR1ESR2
SCHEMBL5729577 0.81 CHEK1 (0.42) CHEK2SSTR2CHEK1ESR1ESR2
SCHEMBL5729693 0.81 CHEK1 (0.42) CHEK2SSTR2CHEK1LMNATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1102755-B1 SUBSTITUTED ISOXAZOLE DERIVATIVES AS ESTROGEN RECEPTOR MODULATORS CHIRON CORP (US) 2006-01-04 EP disclosed
US-6869969-B2 Estrogen receptor modulators CHIRON CORPORATION (US) 2005-03-22 US disclosed
US-6743815-B2 OSTEOPOROSIS; ENDOMETRIOSIS; ALZHEIMER'S DISEASE CHIRON CORPORATION 2004-06-01 US disclosed
US-20040102498-A1 Cycloalkylene compounds with substituents as anticancer agents, atheriosclerosis and estrogen receptors CHIRON CORPORATION 2004-05-27 US disclosed
US-20030065012-A1 Estrogen receptor modulators CHIRON CORPORATION (US) 2003-04-03 US disclosed
US-6387920-B2 ISOXAZOLE COMPOUNDS; FOR TREATING ESTROGEN RECEPTOR-MEDIATED DISORDERS SUCH AS OSTEOPOROSIS, BREAST AND ENDOMETRIAL CANCERS, ATHEROSCLEROSIS, ALZHEIMER'S DISEASE CHIRON CORPORATION 2002-05-14 US disclosed
US-20010036956-A1 Estrogen receptor modulators HUEBNER VERENA D (US) 2001-11-01 US disclosed
US-6262098-B1 ISOXAZOLE ESTROGEN RECEPTOR AGONIST AND ANTAGONIST CHIRON CORPORATION 2001-07-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010036956-A1 Estrogen receptor modulators ESR1, ESR2, GPER1 CHEK2 1773/4885SSTR2 1273/4885CHEK1 2950/4885
US-20030065012-A1 Estrogen receptor modulators ESR1, ESR2, GPER1 CHEK2 1773/4885SSTR2 1273/4885CHEK1 2950/4885
US-20040102498-A1 Cycloalkylene compounds with substituents as anticancer agents, atheriosclerosis and estrogen receptors ESR2, GPER1, ESR1 CHEK2 831/4885SSTR2 387/4885CHEK1 1227/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.